Smith+Nephew's REDAPT(TM) System for revision total hip arthroplasty to be launched in China
One of the pioneers of 3D-printed, imported, acetabular components approved for use in China
LONDON, Sept. 8, 2020 /PRNewswire/ -- Smith+Nephew (LSE: SN, NYSE: SNN), the global medical technology business, announced it has received approval from the National Medical Products Administration (NMPA) in China to introduce its REDAPT System for revision total hip arthroplasty (rTHA). The REDAPT System's acetabular components are among the pioneers of 3D-printed, imported, acetabular product approved for use in China – enabling greater accessibility for customers and patients.
"China has seen rapid growth in primary hip procedures over the past 15-20 years and as such, there is a need for technologies addressing the clinical needs for revision hip arthroplasty," said Ala Ahram, Managing Director Greater China, Smith+Nephew. "Introducing the REDAPT System in China will have a profoundly positive clinical impact to our surgeon customers and will help their patients live a Life Unlimited."
The REDAPT Revision Hip System is distinctively designed to assist surgeons to tackle the challenges of revision hip arthroplasty: fixation in various bone types, achievement of joint stability, predictable stem position, and surgical efficiency.
The 3D-printing process used to manufacture standard "off the shelf" acetabular components enables product features that might normally be cost prohibitive.
Revision total hip arthroplasty procedure volume is expected to increase globally as younger, more active patients, out-live their original implants.
The REDAPT System is designed to deliver reliable stability and help lower the re-revision rate of rTHAs by reducing the frequency of implant movement– a major contributor to early failure of total hip arthroplasty.
"Titanium tapered stems - particularly those with aggressive tapers like REDAPT - have really changed the face of revision hip arthroplasty in the last decade and have made what was a previously complex procedure much more straightforward," said Prof. Fares S. Haddad MD, Professor of Orthopaedic and Sports Surgery, University College of London. "They sit where planned and hold position following surgery; they have become our workhorse for femoral revision."
The addition of the REDAPT System expands Smith+Nephew's comprehensive portfolio of both primary and revision hip arthroplasty products now available in China. The REDAPT System is available in most major global markets and will be commercially available in China later this year.
- Paprosky Classifications I-IV of Femoral Bone Loss
Gabor J, Padilla J, Feng J, et al. Short-term outcomes with the REDAPT monolithic, tapered, fluted, grit-blasted, forged titanium revision femoral stem.
Smith+Nephew is a portfolio medical technology business that exists to restore people's bodies and their self-belief by using technology to take the limits off living. We call this purpose 'Life Unlimited'. Our 17,500+ employees deliver this mission every day, making a difference to patients' lives through the excellence of our product portfolio, and the invention and application of new technologies across our three global franchises of Orthopaedics, Advanced Wound Management and Sports Medicine & ENT.
Founded in Hull, UK, in 1856, we now operate in more than 100 countries, and generated annual sales of $5.1 billion in 2019. Smith+Nephew is a constituent of the FTSE100 (LSE: SN, NYSE: SNN). The terms 'Group' and 'Smith+Nephew' are used to refer to Smith & Nephew plc and its consolidated subsidiaries, unless the context requires otherwise.
Any reposting, distribution or quotation of the above content or any part thereof shall require the prior written consent of Smith+Nephew. Nothing on this webpage should be construed as medical or clinical advice. For more information on the application of any products discussed in this webpage, as well as indications for use, contraindications, and product safety information, please consult the Instructions for Use (IFU) for such product and qualified healthcare professionals.
This document may contain forward-looking statements that may or may not prove accurate. For example, statements regarding expected revenue growth and trading margins, market trends and our product pipeline are forward-looking statements. Phrases such as "aim", "plan", "intend", "anticipate", "well-placed", "believe", "estimate", "expect", "target", "consider" and similar expressions are generally intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other important factors that could cause actual results to differ materially from what is expressed or implied by the statements. For Smith+Nephew, these factors include: economic and financial conditions in the markets we serve, especially those affecting health care providers, payers and customers; price levels for established and innovative medical devices; developments in medical technology; regulatory approvals, reimbursement decisions or other government actions; product defects or recalls or other problems with quality management systems or failure to comply with related regulations; litigation relating to patent or other claims; legal compliance risks and related investigative, remedial or enforcement actions; disruption to our supply chain or operations or those of our suppliers; competition for qualified personnel; strategic actions, including acquisitions and dispositions, our success in performing due diligence, valuing and integrating acquired businesses; disruption that may result from transactions or other changes we make in our business plans or organisation to adapt to market developments; and numerous other matters that affect us or our markets, including those of a political, economic, business, competitive or reputational nature. Please refer to the documents that Smith+Nephew has filed with the U.S. Securities and Exchange Commission under the U.S. Securities Exchange Act of 1934, as amended, including Smith+Nephew's most recent annual report on Form 20-F, for a discussion of certain of these factors. Any forward-looking statement is based on information available to Smith+Nephew as of the date of the statement. All written or oral forward-looking statements attributable to Smith+Nephew are qualified by this caution. Smith+Nephew does not undertake any obligation to update or revise any forward-looking statement to reflect any change in circumstances or in Smith+Nephew's expectations.
™ Trademark of Smith+Nephew. Certain marks registered US Patent and Trademark Office.
SOURCE Smith & Nephew plc
Upcoming Life Sciences Events
- April 2021
- NLSDays + NLS Invest Digital - Nordic Life Science Days
- Greater Copenhagen Microbiome Summit 2021
- 4th Annual Neuroscience Innovation Forum